Our Lawyers
Ping Wang
Dr. Ping Wang focuses her practice on all aspects of intellectual property, including patent prosecution, inter partes review, post grand review, interference practice, counseling and opinions regarding patentability, patent invalidity, freedom-to-operate, infringement, design around, and diligence work in connection with mergers and acquisitions in the biotechnology industry.
Dr. Wang also handles IPR, patent infringement, and other litigation matters, as
well as licensing negotiations, information technology and academic agreements, and acquisitions of capital for entrepreneurs, start-ups, and institutions. She has played a lead role in inter partes review, which is strengthened by her extensive prior patent experience. Dr. Wang has well-established relationships throughout the world which enables swifter patent prosecution outside of the United States. She is business-oriented and gives detailed attention to developing client concepts into complex and complete applications.
Dr. Wang has extensive experience securing broad scope protection for start-ups, universities, medium and large corporations globally. She negotiates and handles business transactions on behalf of her clients, with a particular focus on business negotiations and transactions between the United States and China. She is knowledgeable about all aspects of life science and has experience providing legal advice to clients in the pharmaceuticals, biotechnology, chemical/organic chemistry, medical devices, and artificial intelligence industries.
AWARDS AND RECOGNITION
• IP Star, National and Washington, D.C., 2020-2021
• Managing Intellectual Property, IP Stars, Patent Star, 2020
• IAM Global Leaders, Patent Prosecution, 2020-2021
• IAM Patent 1000, Patent Prosecution, 2012-2021
• Chambers USA, Intellectual Property: Patent Prosecution 2021
• National Law Journal, Intellectual Property Trailblaizer, March 2019
• US Legal 500, Leading Patents: Licensing, and Patents: Prosecution Lawyer
• Elliot Stellar Award from the Philadelphia Chapter, Society for Neuroscience
• Lapides Award from the American Urological Society
PROFESSIONAL ASSOCIATIONS
• American Bar Association
• American Intellectual Property Law Association – Interference Committee,
Biotechnology Committee, Licensing Committee
• American Health Law Association
• American International Law Association
• United States Patent and Trademark Office, Biotechnology, Chemical and
Pharmaceutical Partnership
• Society for Neuroscience
• International Brain Research Organization
PUBLICATIONS
LEGAL PUBLICATIONS
• Coronavirus Drug Shows Global Hurdles to Patent Protection, Co-Author,
Law360, February 2020
• Gene Therapy Policies Can Strike an Ethical Balance, Co-Author, Law360, May
2019
• New USPTO Guidance May Help Diagnostics Patents, Co-Author, Law360,
April 2019
• New Proposed Rules Regarding Government Rights in Federally Funded
Research: Bayh-Dole Act, Co-Author, The National Law Review, February 21,
2017
• Federal Circuit Clari ies the Steps in Biosimilars Dance, Co-Author, The
National Law Review, July 24, 2015
• Presumption of Validity Triumphs over a Good-Faith Belief of Invalidity, Co-
Author, The National Law Review, May 28, 2015
• Post Exclusivity Issues For Biologics, Co-Author, The National Law Review,
January 3, 2015
• The Myriad Decision in the U.S. Supreme Court, Co-Author, The National Law
Review, July 11, 2012
• Is an Isolated DNA Patentable?, Co-Author, The National Law Review, October
27, 2011
SCIENTIFIC PUBLICATIONS
• Luthin, G.R., Wang, P., Zhou, H., Dhanasekaran, D., and Ruggieri, M. Role of
m1 receptor-G Protein coupling in cell proliferation in the prostate. Ann. N.Y.
Acad. Sci. Vo160, Nos. 13/14 (1997)
• Tian, X.H., Gu, J.F., Sun, C.P., and Wang, P. An EPR study of the
neuroprotective effect of the sulfated polysaccaride from Laminaria Japonica.
Soc. Neurosci. 15: 2187 (1997)
• Wang, P., Dhanasekaran, N.E. and Luthin, G.R. ERK activation and cellulary
proliferation in response to muscarinic acetylcholine receptor agonist. Ann N.Y.
Acad. Sci. (1996)
• Wang, P., Luthin, G.R., and Ruggieri, M.R. Muscanrinic acetylcholine receptors
mediating urinary bladder contractility and coupling to GTP binding proteins. J.
Pharmacal. Expt. Ther. 273:959-966 (1995)
• Wang, P., Dhanasekaran, N.D. and Luthin, G.R. ERK activation and cellular
proliferation in response to muscarinic acetylcholine receptor agonist. Receptor
Classification, Verona, Italy (1995)
• Ruggieri, M.R., Colton, M.D., Wang, P., Smyth, R.J., Pontari, M.A., and Luthin,
G.R. Human prostate muscarinic receptor subtypes. J. Pharmacal.Expt. Ther.
274:976-982 (1995)
• Wang, P., Dhanasekaran, N.D. and Luthin, D.R. ERK activation and cellular
proliferation in response to muscarinic acetylcholine receptor agonist. Receptor
Classification, Verona, Italy (1995)
• Ruggieri, M.R., Colton, M.D., Wang, P., Smyth, R.J., Ontari, M.A., and Luthin,
G.R. Human prostate muscarinic receptor subtypes studied. Am. Urol. Assn.
Today 8:1-13 (1995)
• Wang, P., Luthin, G.R., and Ruggieri, M.R. Muscarinic acetylcholine receptor
subtypes mediating urinary bladder contractility and coupling to GTP binding
proteins. J. Urol. Survey Section (1995)
• Wang, P., Ruggieri, M.R., and Luthin, G.R. Biochemical analysis of urinary
bladder muscarinic receptor subtypes. J. Urol., Soc. Basic Urol. Res. Suppl.,
San Francisco, CA (1994)
• Colton, M.D., Wang, P., Cawley, T.A., Luthin, G.R., and Ruggieri, M.R. Effect of
experimental hyperreflexia on rabbit bladder muscarinic receptor subtypes. J.
Urol. 151 :482A (1994)
• Ruggieri, M.R., Colton, M.D., Wang, P., Smyth, R.J., Pontari, M.A., and Luthin,
G.R. Human prostate muscarinic receptor subtypes. J. Urol. 151:380A (1994)
• Ruggieri, M.R., Colton, M.D., Wang, P., Smyth, R.J., Pontari, M.A., and Luthin,
G.R. Human prostate muscarinic receptor subtypes. Soc. Basic Urol. Res.,
Houston, TX (1993)
• Smyth, R.J., Ruggieri, M.R., Colton, M.D., Wang, P., Shickley, T.J., and Luthin,
G.R. Prostate gland contains high levels of the m1 subtype of muscarinic
receptor. Soc. Neurosci. 19:1786 (1993)
• Wang, P., and Luthin, G.R. Stable association of m3 muscarinic receptors and
G proteins. Soc. Neurosci. 19:1768 (1993)
• Cawley, T.A., Wang, P., Ruggieri, M.R., and Luthin, G.R. Muscarinic
acetylcholine receptors in urinary bladder. Soc. Neurosci. 19:1767 (1993)
• Ruggieri, M.R., Cawley, T.A., Wang, P., Hicks, S.E., and Luthin, G.R. Urinary
bladder muscarinic receptor subtypes; effect of chronic neuroleptic treatment.
Incontinence Soc., Halifax, Nova Scotia (1992)
AREAS OF FOCUS
• Intellectual Property
• Patent Counseling and
Prosecution
• Life Sciences
• Intellectual Property Litigation
EDUCATION
• University of New Hampshire,
Franklin Pierce Law Center
J.D.
• Kunming Medical University
M.D.
PREVIOUS EXPERIENCE
• Morris, Manning & Martin,
LLP (Partner)
• Hunton Andrews Kurth LLP
(Partner)
ADMISSIONS
• District of Columbia
• State of Maryland
LANGUAGES
• English
• Mandarin
Michael Ye
Dr. Michael Ye has extensive experience in patent prosecution, opinion work, due diligence and licensing, as well as trademark prosecution and licensing, and copyright. Dr. Ye has handled drafting and prosecuting patent applications globally, inter partes review and post grant proceedings, product clearance searches, product evaluations, inventorship analysis, non-disclosure agreements and licensing agreements. He has substantial experience across the breadth of life sciences, in particular in biotechnology, chemistry/organic chemistry, bioinformatics, cosmetics, pharmaceuticals, medical devices, agriculture and artificial intelligence.
Dr. Ye is named among the worlds leading patent practitioners in IAM Patent
1000, the top worldwide guide to leading patent professionals and firms. Dr. Ye
has extensive experience in inbound and outbound negotiations and business
transactions in China. His cultural sensitivities, linguistics capabilities and technical expertise enhance his successful prosecution, opinion, due diligence and licensing work. Dr. Ye focuses on securing commercially valuable claims that align with clients business strategies, as well as identifying and developing licensing opportunities globally. He provides advice and strategic overview regarding management and development of patent portfolios, including advice on licensing and trademarks.
Prior to legal practice, Dr. Ye was an assistant professor of biochemistry and
molecular biology at George Washington University and Children’s National Medical Center from 1997 to 2002. His research experience included areas such as gene and cell therapy, transgenics, molecular immunology and vaccine development.
Dr. Ye has authored or co-authored 28 peer-reviewed scientific articles, including an article in the prestigious journal Science. He was the recipient of the National Institutes of Health’s National Research Service Award and the recipient of the Award for Scientific and Academic Achievement from the Children’s Medical Center.
AWARDS AND RECOGNITION
• IAM Patent 1000: Patent Prosecution, 2016, 2017, 2020, 2021
• Chambers USA, Intellectual Property: Patent Prosecution, 2021
PUBLICATIONS
LEGAL PUBLICATIONS
• Commercialization strategies for early stage drug-related startups – Co-Auther,
Westlaw Journal (March 25, 2020)
• Coronavirus Drug Shows Global Hurdles to Patent Protection, Co-Author,
Law360, February 2020
• New USPTO Guidance May Help Diagnostics Patents, Co-Author, Law360,
April, 2019
• New Proposed Rules Regarding Government Rights in Federally Funded
Research: Bayh-Dole Act, Co-Author, The National Law Review, February, 2017
• Winning The Battle But Losing The War? – New Considerations For File
Wrapper Estoppel – Co-Auther IP Law360 (December 22, 2014)
• The Myriad Decision in the U.S. Supreme Court, Co-Author, The National Law
Review, July, 2012
• Is an Isolated DNA Patentable?, Co-Author, The National Law Review, October,
2011
SCIENTIFIC PUBLICATIONS (SELECTED FROM 28 PEER-REVIEWED PUBLICATIONS)
• X. Ye, J. McCarrick, L. Jewett and B.B. Knowles, “Timely immunization subverts
the development of peripheral nonresponsiveness and suppresses tumor
development in simian virus 40 tumor antigen-transgenic mice” Proc. Natl.
Acad. Sci. USA 91, 3916-3920, 1994.
• F. Engelhardt, X. Ye, B. Doranz and J.M. Wilson, “Ablation of E2A in
recombinant adenoviruses improves transgene persistence and decreases
inflammatory response in mouse liver” Proc. Natl. Acad. Sci. USA 91,
6196-6200, 1994.
• X. Ye, M.B. Robinson, M.L. Batshaw, E.E. Furth, I. Smith and J.M. Wilson,
“Prolonged metabolic correction in adult ornithine transcarbamylase deficiency
mice with adenoviral vectors” J. Biol. Chem. 271, 3639-3646, 1996.
• X. Ye, G. Gao, Carol Pabin, S. E. Raper and J. M. Wilson, “Evaluating the
potential of germline transmission after intravenous administration of
recombinant adenovirus in the C3H mouse” Hum. Gene Ther. 9, 2135-2142,
1998.
• X. Ye, V.M. Rivera, P. Zoltick, F. Cerasoli, M.A. Schnell, G. Gao, J.V. Hughes, M.
Gilman and J.M. Wilson, “Regulated delivery of therapeutic proteins following in
vivo somatic cell gene transfer” Science, 283, 88-91, 1999.
• M. Rivera, X. Ye, N.L. Courage, F. Cerasoli Jr., J.M. Wilson and M. Gilman,
“Long-term regulated gene expression in mice following intramuscular gene
transfer” Proc. Natl. Acad. Sci. USA, 96:8657-8662, 1999.
• X. Ye, M. Jerebtsova and P.E. Ray, “Liver bypass significantly increases the
transduction efficiency of recombinant adenoviral vectors in the lung, intestine
and kidney” Hum Gene Ther, 11:621-628, 2000.
• X. Ye, B. Whiteman, M. Jerebtsova and M.L. Batshaw, “Correction of
argininosuccinate synthetase (AS) deficiency in a murine model of citrullinemia
with recombinant adenovirus carrying human AS cDNA” Gene Ther,
7:1777-1782, 2000.
• X. Ye, M.B. Robinson, C. Pabin, M.L. Batshaw and J.M. Wilson, “Transient
depletion of CD4 lymphocyte improves efficacy of repeated administration of
recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur
mice” Gene Ther, 7:1761-1767, 2000.
• X. Ye, X. Liu, Z. Li and P.E. Ray, “Efficient gene transfer to rat renal glomeruli
with recombinant adenoviral vectors” Hum Gene Ther, 12:141-148, 2001.
• X. Ye, K.P. Zimmer, R. Brown, C. Pabin, M.L. Batshaw, J.M. Wilson and M.B.
Robinson, “Differences in the human and mouse amino terminal leader
peptides of ornithine transcarbamylase affect mitochondrial import and efficacy
of adenoviral vectors” Hum Gene Ther. 12: 1035-1046, 2001.
• X. Ye, M. Jerebtsova, X. Liu, Z. Li and P.E. Ray, “Adenovirus-mediated gene
transfer to renal glomeruli in rodents” Kidney International 61 Suppl 1:16-23,
2002.
AREAS OF FOCUS
• Patent Counseling and
Prosecution
• China
• Intellectual Property
• Trademark and Copyright
• Technology Licensing
EDUCATION
• Georgetown University
(J.D.)
• University of Pennsylvania
(Ph.D. Biochemistry and Molescular
Biology)
• Peking University
(B.S., Biochemistry)
PREVIOUS EXPERIENCE
• Morris, Manning & Martin LLP
(Partner)
• Andrews Kurth Kenyon
(Partner)
ADMISSIONS
• District of Columbia
• State of Maryland
LANGUAGES
• English
• Mandarin
John Murray
Dr. John Murray has extensive experience in complex life sciences patent litigation, prosecution and opinion work, as well as due diligence. John conducts prosecution both domestically and internationally for a wide range of clients, including start-ups and academic clients, as well as larger corporations. He has substantial experience in life sciences, in areas such as biotechnology, chemistry/organic chemistry, medical devices, molecular biology, and pharmaceuticals, as well as other diverse fields such as software and acoustic technology.
John has significant experience in patent infringement litigation, Hatch-Waxman and ITC 337 litigation. He has particular experience in motion practice, claim construction, discovery work and oral argument. In addition to life sciences litigation. John has also handled litigation involving software, mechanical devices, commercial packaging, and contractual disputes related to IP ownership.
John has handled inter partes review, including oral argument before the USPTO Patent Trial and Appeal Board, as well as appeal to the Federal Circuit.
John received his PhD in molecular genetics under the supervision of Professor
Sir Alec J. Jeffreys from the University of Leicester, England. He completed a
Post-Doctoral Fellowship at Columbia University, after finishing a Post-Doctoral
Fellowship at Mt. Sinai School of Medicine in New York. His post-doctoral research investigated the structural biology of cell membrane proteins through use of x-ray crystallography.
SELECTED EXPERIENCE
• Genetic Technologies, Ltd. V. Histogenetics, LLC, (D. Del.) – Represented
diagnostics innovator in patent infringement litigation to secure dismissal on
summary judgment of patent infringement claims by patent troll.
• Hypoxico Inc. v. Colorado Altitude et al. (S.D.N.Y.) – Represented oxygen
tent manufacturer in trial team to obtain million dollar damage award in patent
infringement litigation jury trial.
• Certain Products Having Laminated Packaging, and Components Thereof
(I.T.C.) – Represented major distiller, including conduct and co-ordination of
discovery, in landmark ITC case to establish failure to meet domestic industry
requirement by patent troll.
• AstraZeneca Ab et al. v. IVAX Corporation et al., (D.N.J.) – Represented generic
against brand name in ANDA litigation to secure settlement before trial.
• Oral argument before the United States Patent Trial and Appeal Board during
IPR proceedings.
AWARDS AND RECOGNITION
• New York Rising Star in Intellectual Property Litigation, Super Lawyers
PUBLICATIONS
• Coronavirus Drug Shows Global Hurdles to Patent Protection, Co-Author,
Law360, February 2020
• Gene Therapy Policies Can Strike an Ethical Balance, Co-Author, Law360, May
2019
• New USPTO Guidance May Help Diagnostics Patents, Co-Author, Law360,
April 2019
• New Proposed Rules Regarding Government Rights in Federally Funded
Research: Bayh-Dole Act, Co-Author, The National Law Review, February 21,
2017
• Federal Circuit Clarifies the Steps in Biosimilars Dance, Co-Author, The
National Law Review, July 24, 2015
• Presumption of Validity Triumphs over a Good-Faith Belief of Invalidity, Co-
Author, The National Law Review, May 28, 2015
• Post Exclusivity Issues For Biologics, Co-Author, The National Law Review,
January 3, 2015
• Winning the Battle But Losing The War? – New Considerations For File
Wrapper Estoppel, December 22, 2014
• The Supreme Court Takes on Patent Trolls, Technophilic Magazine, February
12, 2014
• Provisionally Protecting Your Next Genius Idea, October 2013
• Be Quick or You’ll Lose: The New First-to-File Patent Application Rule,
December 2012
• The New Post-Grant Patent Review: Just When You Thought You Were Out,
They Pull You Back In, July 2012
• Challenges to Stem Cell Patents in Europe and the U.S., The Intellectual
Property Strategist, December 2007
• Podcast: Lab Bench Meets Federal Bench: The Supreme Court and Stem Cell
Research, February 15, 2013, The New York Academy of Science (NYAS)
SCIENTIFIC PUBLICATIONS
• Titus J Boggon, John Murray, Sophie Chappuis-Flament, Ellen Wong,
Barry M Gumbiner, Lawrence Shapiro. C-cadherin ectodomain structure
and implications for cell adhesion mechanisms. Science. 2002 May
17;296(5571):1308-13.
• Murray J, Buard J, Neil DL, Yeramian E, Tamaki K, Hollies C, Jeffreys AJ.
Comparative sequence analysis of human minisatellites showing meiotic repeat
instability. Genome Res. 1999 Feb;9(2):130-6.
• A J Jeffreys, J Murray, R Neumann. High-resolution mapping of crossovers
in human sperm defines a minisatellite-associated recombination hotspot. Mol
Cell. 1998 Aug;2(2):267-73.
• Jeffreys AJ, Bois P, Buard J, Collick A, Dubrova Y, Hollies CR, May CA, Murray
J, Neil DL, Neumann R, Stead JD, Tamaki K, Yardley J. Spontaneous and
induced minisatellite instability. Electrophoresis. 1997 Aug;18(9):1501-11.
AREAS OF FOCUS
• Intellectual Property
• Intellectual Property Litigation
• Life Sciences
• Patent Counseling and
Prosecution
EDUCATION
• Fordham University 2006
J.D., cum laude
• Columbia University
Post-Doctoral Fellow
• Mt. Sinai School of Medicine
Post-Doctoral Fellow
• University of Leicester
Ph.D., Molecular Genetics
• University of Edinburgth
B.S., Biological Sciences (Genetics)
PREVIOUS EXPERIENCE
• Morris, Manning & Martin,
LLP (Of Counsel)
• Andrews Kurth LLP (Of
Counsel)
ADMISSIONS
• District of Columbia
• State of New York
• U.S. District Court for the
Northern District of New York
• U.S. District Court for the
Southern District of New York
• U.S. Patent and Trademark
Office (USPTO)
Petr VanderVegt
Dr. F Pierre (Petr) VanderVegt is a seasoned patent practitioner with nearly 30 years of experience in intellectual property and technology transfer. This includes 11 years as a biotechnology patent examiner at the USPTO, four years as an intellectual property manager at a leading military medicine research organization, and stints at AmLaw100 firms. His practice includes patent preparation and prosecution in the U.S. and foreign jurisdictions, portfolio
management, as well as assisting attorneys in the preparation of freedom-to-operate, patentability, infringement, and due diligence opinions. He also provides research support for litigation matters and has drafted and managed inter-institutional and material transfer agreements. Petr’s patent preparation and prosecution experience include technologies such as gene therapy,
immunology, medical devices, diagnostics and therapeutics, emergency medicine in austere environments, biological countermeasures, cell purification and sample handling systems, as well as protective and environmental control barriers. Petr’s doctoral and postdoctoral research focused on autoimmunity and transplantation. He was part of the team that identified islet antigen 2 (IA-2), a protein tyrosine phosphatase that is a
major target of autoimmune response in type 1 diabetes and involved in the destruction of pancreatic beta cells.
SCIENTIFIC PUBLICATIONS
- Maclaren N, Lan M, Coutant R, Schatz D, Silverstein J, Muir A, Clare-Salzer M, She J-
- X, Malone J, Crockett S, Schwartz S, Quattrin T, DeSilva M, VanderVegt P, Notkins A, and Krischer J: Only Multiple Autoantibodies to Islet Cells (ICA), Insulin, GAD65, IA-2 and IA-2.beta. predict Immune-Mediated (Type 1) Diabetes in Relatives. Journal of Autoimmunity. 12(4):279-287. (1999).
- Notkins AL, Lu J, Li Q, VanderVegt FP, Wasserfall C, Maclaren NK and Lan MS: IA-2 and IA-2 are major autoantigens in IDDM and the precursors of the 40 kDa and 37 kDa tryptic fragments. Journal of Autoimmunity. 9(5):677-682. (1996).
- Dumois JA, VanderVegt FP, Kopp JB, Marinos NJ, Rooney JF and Notkins AL: Transplantation of skin from HIV-1 transgenic mice to normal congenic mice results in graft rejection. Journal of Infectious Diseases. 172(1):232-234. (1995).
- VanderVegt FP and Johnson LL: Induction of long-term H-Y specific tolerance in female mice given male lymphoid cells while transiently depleted of CD4+ or CD8+ T cells. Journal of Experimental Medicine. 177(6):1587-1592. (1993).
- Johnson LL, VanderVegt FP and Havell EA: IFN--dependent temporary resistance to acute Toxoplasma gondii infection independent of CD4+ or CD8+ lymphocytes. Infection and Immunity. 61(12):5174-5180. (1993).
- (Poster/Abstract) VanderVegt FP, Oh SJ, Bradley RJ and Dwyer DS: CD5+ B cells in myasthenia gravis patients: Elevated percentage associated with immunosuppressive therapy. New York Academy of Sciences (1992).
- Dwyer DS, VanderVegt FP and Zhou T: Immunogenetics of experimental myasthenia gravis: Contribution of IgVH genes encoding anti-dextran antibodies to immune responsiveness against the acetylcholine receptor. In, "Immunogenetics of Autoimmune Disease. Volume 2". Ed. N. Farid. CRC Press, Inc. Boca Raton, FL (1991).
- Dwyer DS, VanderVegt FP, Bartels J and Brown GB: Monoclonal antibodies against the P2 protein of peripheral myelin and d18 protein of PC12 cells bind to antigen presenting cells and inhibit T cell activation. Annals of the New York Academy of Sciences. 540:452-454. (1988).
- (Abstract) Dwyer DS, Bartels J, VanderVegt FP and Brown GB: Monoclonal antibody interference with cell membrane signaling via putative lipid-binding proteins. Journal of Cellular Biochemistry, 11B:159 (1987).
PREVIOUS EXPERIENCE
- Intellectual Property
- Patent Preparation and Prosecution
- Life Sciences
- Medical Devices
- Protective Barriers and Environmental Management
PREVIOUS EXPERIENCE
- Kilpatrick Townsend & Stockton LLP (Patent Agent)
- Pillsbury Winthrop Shaw & Pittman LLP (Patent Agent)
- Henry M. Jackson Foundation for the Advancement of Military Medicine (IP Manager)
- Morris Manning & Martin LLP (Patent Agent)
- Andrews Kurth, LLP (Patent Agent)
- Mintz Levin, PC (Patent Agent)
- Morgan Lewis & Bockius LLP (Patent Agent)
- U.S. Patent & Trademark Office (Patent Examiner)
EDUCATION
- National Institute of Dental Research, NIH (Postdoctoral Fellow)
- Trudeau Institute, Inc. (Postdoctoral Trainee)
- University of Alabama at Birmingham (Ph.D. – Medical Genetics)
- Eckerd College (B.S. – Biology)
PROFESSIONAL ASSOCIATIONS
- AIPLA
- AUTM